Enhancement of proteasome activity by a small-molecule inhibitor of USP14 - PubMed (original) (raw)
. 2010 Sep 9;467(7312):179-84.
doi: 10.1038/nature09299.
Min Jae Lee, Soyeon Park, Dong-Chan Oh, Suzanne Elsasser, Ping-Chung Chen, Carlos Gartner, Nevena Dimova, John Hanna, Steven P Gygi, Scott M Wilson, Randall W King, Daniel Finley
Affiliations
- PMID: 20829789
- PMCID: PMC2939003
- DOI: 10.1038/nature09299
Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Byung-Hoon Lee et al. Nature. 2010.
Abstract
Proteasomes, the primary mediators of ubiquitin-protein conjugate degradation, are regulated through complex and poorly understood mechanisms. Here we show that USP14, a proteasome-associated deubiquitinating enzyme, can inhibit the degradation of ubiquitin-protein conjugates both in vitro and in cells. A catalytically inactive variant of USP14 has reduced inhibitory activity, indicating that inhibition is mediated by trimming of the ubiquitin chain on the substrate. A high-throughput screen identified a selective small-molecule inhibitor of the deubiquitinating activity of human USP14. Treatment of cultured cells with this compound enhanced degradation of several proteasome substrates that have been implicated in neurodegenerative disease. USP14 inhibition accelerated the degradation of oxidized proteins and enhanced resistance to oxidative stress. Enhancement of proteasome activity through inhibition of USP14 may offer a strategy to reduce the levels of aberrant proteins in cells under proteotoxic stress.
Figures
Figure 1. Usp14 is an inhibitor of the proteasome
a, Ub-AMC hydrolysis assay of Usp14 activity in the presence or absence of Ub-VS treated human proteasome (VS-proteasome; 1 nM). RFU, relative fluorescence units. Ptsm, 26S proteasome. b, In vitro degradation assay with polyubiquitinated cyclin B (Ubn-ClnB), human proteasome (4 nM), and wild-type Usp14 (Usp14-wt) or mutant Usp14-CA (60 nM). Samples in b, c, and e-h analyzed by SDS-PAGE/immunoblotting (IB). c, Plasmids expressing Tau, TDP-43Flag, or LacZV5 were cotransfected into _usp14_−/− MEFs with variants of Usp14Flag as indicated. Samples collected 2 days post-transfection. Actin, load control. d, Diagram of human Usp14, showing ubiquitin-like (UBL) and catalytic (CAT) domains. C114, active site cysteine. Splice variant Usp14-SF is produced from an mRNA lacking exon 4 (ref 12). e, Flag-tagged Ataxin3-Q22 or -Q80 was coexpressed with Usp14 variants in _usp14_−/− MEFs and detected with anti-Flag antibodies. f, Arg-GFP or control Met-GFP coexpressed with Usp14 variants in _usp14_−/− MEFs. g, As c except in HEK293 cells. h, Usp14-SF associates with but is not activated by proteasomes. Each variant of Usp14Flag was expressed in HEK293T cells containing tagged hRpn11, and proteasomes were affinity purified. Where indicated, Ub-VS was incubated with lysate prior to proteasome purification. Extract samples represent 5% of total. Asterisks, nonspecific signals. Proteasome subunit Rpn13, load control. Control samples, empty vector. Equal cell numbers were used for each lane.
Figure 2. IU1 inhibits human Usp14 specifically and reversibly
a, Chemical structures of IU1 and IU1C. Analytical data shown in Supplementary Fig. 16. b, IC50 determination for IU1 inhibition of Ub-AMC hydrolysis by proteasome-bound Usp14 (4.7 ± 0.7 μM), IsoT (100 ± 0.4μM), and Uch37 (0.7 ± 0.3 mM). c, Ub-AMC (1 μM) hydrolysis assays showing specificity of IU1 for Usp14. d, Reversibility of Usp14 inhibition. 60 nM Usp14 and 5 nM human proteasome were treated with vehicle (DMSO) or 100 μM IU1 for 2 hr. After spin gel-filtration, proteins were assayed for Ub-AMC hydrolysis. All values are presented as mean ± s.d. (n=3).
Figure 3. IU1 inhibits chain trimming and stimulates substrate degradation in vitro
a, Chain trimming assays. Samples contained 4 nM proteasome, and Usp14 was added at 15-fold molar excess over proteasome. IU1 was added at 50 μM and proteasome inhibitors (PI) at 5 μM (PS-341, epoxomicin). Asterisk, cyclin B species derived from residual thrombin from Usp14 preparation. All panels, SDS-PAGE/immunoblot analysis. b, In vitro Ubn-ClnB degradation assay (IU1 at 34 μM). c, In vitro degradation assay with polyubiquitinated Sic1PY, human proteasome (5 nM), and Usp14-wt (75 nM) in the absence or presence of IU1 (75 μM).
Figure 4. IU1 enhances proteasomal degradation in vivo
All panels show SDS-PAGE/immunoblot data. a, 36 hours after cotransfecting wild-type MEFs with plasmids expressing Tau and LacZV5, cells were incubated with 0, 25, 50, 75, or 100 μM of IU1 for 6 hr. LacZ, transfection control. Actin, loading control. b, As in a except that MEFs were _usp14_−/− and IU1 was at 0, 10, 50, or 100 μM. c, Tau and Ub-independent proteasome substrate cODC-EGFP were coexpressed in wild-type MEFs and incubated with 50 μM IU1 for 6hr. Proteasome inhibitors were MG132 (30 μM) and PS-341 (10μM). d, As b except with Atx3-Q80 and Atx3-Q22. e, TDP-43Flag was cotransfected with a LacZ-expressing plasmid into either wild-type or _usp14_−/− MEFs, then treated with IU1 (75 μM) for the time indicated. Asterisk, nonspecific signal. f, HA-tagged Ub and/or Flag-tagged TDP-43 were transiently overexpressed in wild-type MEFs with 50μM IU1 incubation for 6 hr. Proteasome inhibitors (20 μM MG132, 10 μM PS-341) were added 4 hr before lysis. Lysates were subjected to immunoprecipitation with anti-HA or anti-Flag. Arrows indicate likely ubiquitinated TDP-43 species. HC, heavy chain. g, Wild-type MEF and _usp14_−/− MEF cells were treated with IU1 (0, 25, 50, 75, or 100 μM) for 6 hr, followed by analysis for ubiquitin, actin, CP subunit α7, and RP subunit Rpt5.
Figure 5. IU1 alleviates cytotoxicity induced by oxidative stress
a, HEK293 cells were preincubated with IU1 (75 μM) or proteasome inhibitors (20 μM MG132, 10 μM PS-341) for 4 hr, then treated with menadione (300 μM) for 60 min. Lysates were treated with DNPH and immunoblotted with anti-DNP antibody to assay oxidized proteins. b, Cell survival under oxidative stress measured using the MTT assay. HEK293 cells were pretreated with 50 μM IU1 for 2 hr. Menadione was added, followed by 4-hr incubation. IU1 effects comparable to those of panels a and b were obtained in wild-type but not _usp14_−/− MEFs (data not shown). Values are represented as mean ± s.d. (n=3).
Similar articles
- Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c.
Kuo CL, Goldberg AL. Kuo CL, et al. Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3404-E3413. doi: 10.1073/pnas.1701734114. Epub 2017 Apr 10. Proc Natl Acad Sci U S A. 2017. PMID: 28396413 Free PMC article. - Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity.
Lee JH, Shin SK, Jiang Y, Choi WH, Hong C, Kim DE, Lee MJ. Lee JH, et al. Sci Rep. 2015 Jun 4;5:10757. doi: 10.1038/srep10757. Sci Rep. 2015. PMID: 26041011 Free PMC article. - In vitro analysis of proteasome-associated USP14 activity for substrate degradation and deubiquitylation.
Muniyappan S, Lee BH. Muniyappan S, et al. Methods Enzymol. 2019;619:249-268. doi: 10.1016/bs.mie.2018.12.028. Epub 2019 Feb 1. Methods Enzymol. 2019. PMID: 30910023 - Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes.
Lee MJ, Lee BH, Hanna J, King RW, Finley D. Lee MJ, et al. Mol Cell Proteomics. 2011 May;10(5):R110.003871. doi: 10.1074/mcp.R110.003871. Epub 2010 Sep 7. Mol Cell Proteomics. 2011. PMID: 20823120 Free PMC article. Review. - Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
Moon S, Muniyappan S, Lee SB, Lee BH. Moon S, et al. Int J Mol Sci. 2021 Jun 9;22(12):6213. doi: 10.3390/ijms22126213. Int J Mol Sci. 2021. PMID: 34207520 Free PMC article. Review.
Cited by
- Understanding neurodevelopmental proteasomopathies as new rare disease entities: A review of current concepts, molecular biomarkers, and perspectives.
Cuinat S, Bézieau S, Deb W, Mercier S, Vignard V, Isidor B, Küry S, Ebstein F. Cuinat S, et al. Genes Dis. 2023 Sep 26;11(6):101130. doi: 10.1016/j.gendis.2023.101130. eCollection 2024 Nov. Genes Dis. 2023. PMID: 39220754 Free PMC article. Review. - Usp14 down-regulation corrects sleep and circadian dysfunction of a Drosophila model of Parkinson's disease.
Favaro M, Mauri S, Bernardo G, Zordan MA, Mazzotta GM, Ziviani E. Favaro M, et al. Front Neurosci. 2024 Aug 5;18:1410139. doi: 10.3389/fnins.2024.1410139. eCollection 2024. Front Neurosci. 2024. PMID: 39161651 Free PMC article. - Floxuridine supports UPS independent of germline signaling and proteostasis regulators via involvement of detoxification in C. elegans.
Dubey AA, Sarkar A, Milcz K, Szulc NA, Thapa P, Piechota M, Serwa RA, Pokrzywa W. Dubey AA, et al. PLoS Genet. 2024 Jul 31;20(7):e1011371. doi: 10.1371/journal.pgen.1011371. eCollection 2024 Jul. PLoS Genet. 2024. PMID: 39083540 Free PMC article. - The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias.
Zhang H, Wang X. Zhang H, et al. Cerebellum. 2024 Jul 25. doi: 10.1007/s12311-024-01722-w. Online ahead of print. Cerebellum. 2024. PMID: 39052145 Review. - Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, Lu B, Fan Y, Liu Z, Chen X, Jia X, Dong Z, Liu K. Liu F, et al. Mol Cancer. 2024 Jul 25;23(1):148. doi: 10.1186/s12943-024-02046-3. Mol Cancer. 2024. PMID: 39048965 Free PMC article. Review.
References
- Verma R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298:611–615. - PubMed
- Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature. 2002;419:403–407. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R56 GM066492/GM/NIGMS NIH HHS/United States
- GM65592/GM/NIGMS NIH HHS/United States
- DK082906/DK/NIDDK NIH HHS/United States
- R01 GM065592/GM/NIGMS NIH HHS/United States
- NS047533/NS/NINDS NIH HHS/United States
- R01 NS047533-06A2/NS/NINDS NIH HHS/United States
- R21 DK082906/DK/NIDDK NIH HHS/United States
- R01 GM067945/GM/NIGMS NIH HHS/United States
- P30 NS057098-049002/NS/NINDS NIH HHS/United States
- R01 GM066492/GM/NIGMS NIH HHS/United States
- P30 NS057098/NS/NINDS NIH HHS/United States
- GM66492/GM/NIGMS NIH HHS/United States
- R01 NS047533/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases